Related Experiment Video
Updated: Jun 24, 2026

Induction of Mouse Lung Injury by Endotracheal Injection of Bleomycin
Published on: April 30, 2019
Therapy-induced toxicity of the lungs: an overview
Andriani G Charpidou1, Ioannis Gkiozos, Sotirios Tsimpoukis
1Oncology Unit, Third Department of Medicine, Athens School of Medicine, Sotiria General Hospital, Athens, Greece.
Unlabelled:
Pulmonary toxicity induced by novel antineoplastic agents has not been well characterized because of the simultaneous or sequential use of drugs and a multimodality therapeutic approach. To further investigate this topic, relevant studies were identified through Medline. The generic names of novel antineoplastic agents and the key words pulmonary toxicity, dyspnea and pneumonitis were used for the search. References from the articles identified were also reviewed for additional sources. Most novel antineoplastic drugs may induce pulmonary toxicity. The most recognized patterns of lung toxicity consist of unspecified dyspnea and interstitial lung disease (ILD). Exclusion diagnosis of possible underlying diseases is necessary. Genetic predisposition, autoimmune conditions or superimposed disease may also be involved in the development of lung toxicity.
Conclusion:
Clinicians should be aware of potential pulmonary toxicity as a complication in the treatment of cancer and focus on its early detection or prediction.
Insights
Novel cancer drugs can cause lung problems, often appearing as shortness of breath or interstitial lung disease. Early detection of this pulmonary toxicity is crucial for patient care.
Area of Science:
- Oncology
- Pulmonology
- Pharmacology
Background:
- Pulmonary toxicity from novel antineoplastic agents is not well understood due to complex treatment regimens.
- Simultaneous or sequential drug use and multimodality approaches complicate characterization.
Purpose of the Study:
- To investigate and characterize pulmonary toxicity induced by novel antineoplastic agents.
- To identify common patterns and potential contributing factors of lung toxicity.
Main Methods:
- Literature search using Medline with keywords: novel antineoplastic agents, pulmonary toxicity, dyspnea, and pneumonitis.
- Review of references from identified articles for additional relevant studies.
Main Results:
- Most novel antineoplastic drugs have the potential to induce pulmonary toxicity.
- Common manifestations include unspecified dyspnea and interstitial lung disease (ILD).
- Exclusion diagnosis is necessary; genetic predisposition, autoimmune conditions, or superimposed diseases may play a role.
Conclusions:
- Clinicians must recognize pulmonary toxicity as a potential complication of cancer treatment.
- Focus on early detection and prediction strategies for pulmonary toxicity is essential.
Related Concept Videos
Toxic Reactions: Overview
Toxicity falls into two primary categories: local and systemic.
Local toxicity appears at the exposure site, such as protein denaturation caused by caustic substances.
In contrast, systemic toxicity requires the toxic agent's absorption and distribution,...
Inhalational Anesthetics: Overview
Toxicity Testing in Animals
Drug Toxicity: Overview
Other Pulmonary Disorders
Drug Toxicity: Dose-Dependent Reactions
